117 research outputs found

    Current Perspectives on Western Boreal Forest Life: Ethnographic and Ethnohistoric Research in Late Prehistoric and Historic Archaeology - A Preface

    Get PDF
    At the 1987 Society for American Archaeology Meetings in Toronto, several scholars gathered to present their most recent research using ethnographic and ethnohistoric information to study late prehistoric and historic Athabaskan archaeology in the western subarctic interior. ... The papers from this symposium make up the rest of this volume; this preface provides the reader with some background for better appreciating the papers that follow. The preface begins with a short historical summary of recent Athabaskan archaeology, including the use of ethnohistoric and ethnographic approaches. It continues with very brief summaries of the six papers as context for the subsequent comments, presented at the session by the symposium's two discussants, Polly McW. Quick and Donald W. Clark. Their comments touch on several important issues, including adaptation to environmental variability, the importance of explicit linkages between ethnographic information and archaeology, the value of oral history, the difficulties of projecting findings from recent historic sites back even to more distant historic sites, the promise and problems of interpreting social groupings from structural remains, the value of having northern researchers who live and work throughout the year in the North, and the need for better frameworks for linking ethnographic and ethnohistoric information with archaeology to permit some generalization. The preface closes with a discussion of future research directions and priorities. ...Key words: Alaska, archaeology, Athabaskans, boreal forest, Canada, ethnoarchaeology, ethnography, ethnology, ethnohistory, historic period, research priorities, Subarctic, symposiumMots clés: Alaska, archéologie, Athabaskans, forêt boréale, Canada, ethnoarchéologie, ethnographie, ethnologie, ethnohistoire, période historique, priorité dans la recherche, subarctique, symposiu

    Screening for Popliteal Aneurysms Should not be a Routine Part of a Community-Based Aneurysm Screening Program

    Get PDF
    Martin Claridge1, Simon Hobbs1, Clive Quick2, Donald Adam1, Andrew Bradbury1, Teun Wilmink11University Department of Vascular Surgery, Birmingham Heartlands Hospital, Birmingham, UK; 2Department of Surgery, Hinchingbrooke Hospital, Huntingdon, UKIntroduction: Several studies have found an increased incidence of peripheral aneurysms in patients with an abdominal aortic aneurysm (AAA). The aim of this study was to determine whether screening for popliteal aneurysms should be part of an AAA screening programme.Setting: A community-based AAA screening programmeMethods: The diameters of the internal abdominal aorta and both popliteal arteries were assessed by B-Mode ultrasound in a subgroup of the screened population. An AAA was defined as an infrarenal aortic diameter >29 mm. A popliteal aneurysm was defined as a popliteal diameter >19 mm.Results: Information was available for 283 subjects, 112 subjects with a small AAA, and 171 subjects with a normal aorta. No popliteal aneurysms were found in the subjects with a normal aorta. Three popliteal aneurysms were found in patients with a small AAA. Scanning both popliteal arteries took an experienced sonographer on average three times as long as scanning for an AAA (5 vs 15 minutes).Conclusion: Popliteal artery aneurysms are seen in less than 3% of men with a small AAA and not at all in men with a normal aortic diameter. It is therefore not cost effective to include screening for popliteal aneurysms in population screening for AAA.Keywords: popliteal aneurysm, screening progra

    Fiber optic temperature sensor

    Get PDF
    An inexpensive, lightweight fiber optic micro-sensor that is suitable for applications which may require remote temperature sensing. The disclosed temperature sensor includes a phosphor material that, after receiving incident light stimulation, is adapted to emit phosphorescent radiation output signals, the amplitude decay rate and wavelength of which are functions of the sensed temperature

    Neurophysiology

    Get PDF
    Contains reports on twenty research projects.Bell Laboratories (Grant)National Institutes of Health (Grant 5 R01 EY01149-03S2)National Institutes of Health (Grant 5 TO1 EY00090-04)National Institutes of Health (Grant 5 RO1 NS12307-03)National Institutes of Health (Grant K04 NS00010)National Multiple Sclerosis Society (Grant RG-1133-A-1)Health Sciences Fund (Grant 78-10

    Serum Dioxin Concentrations and Quality of Ovarian Function in Women of Seveso

    Get PDF
    BACKGROUND: Although 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has been associated with alterations in ovarian function and hormones in animals, it has not been studied in humans. On 10 July 1976, an explosion exposed residents of Seveso, Italy, to the highest levels of TCDD in a population. Twenty years later, we initiated the Seveso Women’s Health Study to study reproductive health. OBJECTIVE: We related TCDD levels measured in sera collected near the time of explosion and ovarian function (ovarian cysts, ovarian follicles, ovulation rate, serum hormones) at follow-up. METHODS: We included 363 women who were 20–40 years of age and nonusers of oral contraceptives. We examined the relationship of 1976 serum TCDD levels with ultrasound-detected ovarian follicles among 96 women in the menstrual follicular phase and serum hormone levels (estradiol, progesterone) among 129 women in the menstrual luteal phase at follow-up. Ovulation was defined by serum progesterone levels > 3 ng/mL. RESULTS: The median serum TCDD level was 77.3 ppt, lipid-adjusted. Serum TCDD was not associated with number or size of ovarian follicles. Of women in the luteal phase, 87 (67%) ovulated. Serum log(10)TCDD was not associated with odds of ovulation [adjusted odds ratio = 0.99; 95% confidence interval (CI), 0.5 to 1.9]. Among those who had ovulated, serum log(10)TCDD was not associated with serum progesterone [adjusted beta (adj-β ) = −0.70; 95% CI, −2.4 to 1.0] or estradiol (adj-β = −1.81; 95% CI, −10.4 to 6.8). CONCLUSIONS: We found no clear evidence that 1976 TCDD exposure was associated with ovarian function 20 years later in women exposed to relatively high levels in Seveso, Italy

    Neurophysiology

    Get PDF
    Contains research objectives and summary of research on sixteen research projects.National Institutes of Health (Grant 5 TO1 EY00090-03)National Institutes of Health (Grant 3 RO1 EY01149-03S1)Bell Laboratories (Grant)National Institutes of Health (Grant 5 RO1 NS12307-02)National Institutes of Health (Grant K04 NS00010

    Neurophysiology

    Get PDF
    Contains research objectives and summary of research on seventeen research projects and reports on four research projects.National Institutes of Health (Grant 5 TOl EY00090-02)Bell Telephone Laboratories, Inc. (Grant)National Institutes of Health (Grant 5 ROI EY01149-03)National Institutes of Health (Grant NS 12307-01)National Institutes of Health (Grant 1 K04 NS00010

    Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.

    Get PDF
    UNLABELLED: We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, and who failed front-line regimens containing rituximab. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv.) or gemcitabine 1000 mg/m(2) iv. on days 1, 8 and 15, combined with rituximab 375 mg/m(2) iv. on day 1, up to six cycles. Pixantrone has a conditional European marketing approval for monotherapy in adults with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Our trial explores the efficacy of combining pixantrone with rituximab and completes postauthorization measures. TRIAL REGISTRATION NUMBER: NCT01321541
    • …
    corecore